GTBP - GT Biopharma to target solid tumor cancers with NK-cell based therapy

Announcing the filing of U.S. and international patents, GT Biopharma (GTBP) says it is expanding the clinical development of its NK cell engager (TriKE™) therapeutic platform to target HER2+, HER3+, and HER2+/HER3+ heterodimer complex breast and gastrointestinal cancers.Composed of the variable regions of the heavy and light chains of anti-CD16 and anti-HER2 antibodies and a modified form of IL-15, the molecule’s human IL-15 portion generates a self-sustaining signal to activate NK cells, enhancing their ability to kill cancer cells.The chairman/CEO of GT Biopharma, Anthony Cataldo, says: “We anticipate submitting our IND application to FDA next year requesting allowance to proceed with an evaluation in patients with complex breast and gastrointestinal cancers.”Breast cancer affects an estimated 276,480 patients annually in the U.S., and 15% of breast cancer cells have a high density of human epidermal growth factor receptor 2 (HER2) expressed on the cell's surface. Gastrointestinal cancer, accounting for 7% of all cancers,

For further details see:

GT Biopharma to target solid tumor cancers with NK-cell based therapy